STUDY OF CLINICAL PREDICTIVE FACTORS OF ASIA IN PATIENTS TAKING CHECK-POINT INHIBITOR THERAPY
- Anna M. Malkova, Russian Federation
Abstract
Background and Aims
At the moment, there are no predictive markers of immune adverse events (IAE), which makes timely diagnosis very difficult. In 2011 criteria for determining Autoimmune-Inflammatory syndrome induced by adjuvants (ASIA) were proposed (Y. Shoenfeld, 2011). This study aims to identify the clinical manifestations of ASIA, as well as to determine the extent to which the influence of trigger factors listed in the “ASIA Questionnaire” are significant.
Methods
We examined patients (n=50) being treated for solid tumors at St. Petersburg City Clinical Oncology Center. Among the patients, 30 took nivolumab, 15-pembrolizumab, and 5-combined immunotherapy. To assess the impact of exogenous and endogenous trigger factors, all patients were interviewed using the “ASIA” standardized questionnaire. Supported by Grant (contract № 14.W03.31.0009 13.02.2017).
Results
The signs of ASIA syndrome were found in 72 % (36/50) of patients. The most frequent clinical manifestations were arthralgia-33% (12/36) and rash - 28% (10/36). The development of thyroiditis was detected in 8% (3/36) of cases, and hepatitis in 6% (2/36). No relationship was found between the development of ASIA and the influence of trigger factors, the previous presence of ASIA symptoms, and the type of drug used.
Conclusions
Our results exceed the frequency of complications according to the literature data, which may be due to a more extensive list of analyzed criteria and subjective assessment of the patient's condition. Development of specific complications corresponds to the results of past studies. It was shown that studied ICI induce ASIA symptoms regardless previous clinical symptoms of autoimmune processes and different types of trigger affection.